Sickle cell disease: current therapeutic approaches

Bibliography

• STETSON CA JR: The state of hemoglobin in sickled erythrocytes. J. Exp. Med. (1966) 123(2):341–346.
   PubMed Web of Science ®Google Scholar
• MAGDOFF-FAIRCHILD B, SWERDLOW PH, BERTLES JF: Intermolecular organization of deoxygenated sickle haemoglobin determined by X-ray diffraction. Nature (1972) 239(5369):217–219.
   PubMed Web of Science ®Google Scholar
• BUNN HF, FORGET BG: Hemoglobin: molecular, genetic and clinical aspects. WB Saunders Company, Philadelphia, USA (1986).
   Google Scholar
• EMBURY SH, HEBBEL RP, MOHANDAS N, STEINBERG MH: Sickle Cell Disease: Basic principles and clinical practice. Lippincott-Ravin, Philadelphia/New York, USA (1994).
   Google Scholar
• STEINBERG MH, NAGEL RL: Sickle Cell Disease. In: Disorders of Hemoglobin:Genetics, Pathophysiology and Clinical Management. Steinberg MH, Forget BG, Higgs DR, Nagel RL (Eds), Cambridge University Press, Cambridge, UK (2001).
   Google Scholar
• GOLDBERG MA, BRUGNARA C, DOVER GJ, SCHAPIRA L, LACROIX L, BUNN HF: Hydroxyurea and erythropoietin therapy in sickle cell anemia. Semin. Oncol (1992) 19(3, Supp1.9):74–81.
   Google Scholar
• ROGERS ZR: Hydroxyurea therapy for diverse pediatric populations with sickle cell disease. Semin. Hematol (1997) 34(3, Supp1.3):42–47.
   Google Scholar
• PLATT OS, BRAMBILLA DJ, ROSSE WF et al.: Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J. Med. (1994) 330 (23) :1639–1644.
   PubMed Web of Science ®Google Scholar
• BUCHANAN GR, DEBAUN MR, QUINN CT, STEINBERG MH: Sickle cell disease. Hematology (Am. Soc. Hematol Edu. Program) (2004):35–47.
   Google Scholar
• ABDULMALIK 0, SAFO MK, CHEN Q et al.: 5-Hydroxymethy1-2-furfitral modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells. Br. J. Haematol (2005) 128(4):552–561.
   Google Scholar
• ••Describes for the first time in vivomodification of HbS in a mouse model by an orally administered aromatic aldehyde to prevent RBC sickling.
   Google Scholar
• WARE RE, EGGLESTON B, REDDING -LALLINGER R et al: Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood (2002) 99(1):10–14.
   PubMed Web of Science ®Google Scholar
• ZIMMERMAN SA, SCHULTZ WH, DAVIS JS et al.: Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood (2004) 103(6):2039–2045.
   PubMed Web of Science ®Google Scholar
• ABRAHAM DJ, MEHANNA AS, WIREKO FC, WHITNEY J, THOMAS RP, ORRINGER EP: Vanillin, a potential agent for the treatment of sickle cell anemia. Blood (1991) 77(61:1334–1341.
   PubMedGoogle Scholar
• BALLAS SK: Hydration of sickle erythrocytes using a herbal extract (Pfaffia paniculata) in vitro. Br. J. Haematol (2000) 111(1):359–362.
   PubMed Web of Science ®Google Scholar
• BENNEKOU P, DE FRANCESCHI L, PEDERSEN 0 et al.: Treatment with N53623, a novel Cl-conductance blocker, ameliorates erythrocyte dehydration in transgenic SAD mice: a possible new therapeutic approach for sickle cell disease. Blood (2001) 97(5):1451–1457.
   Google Scholar
• DE FRANCESCHI L, BACHIR D, GALACTEROS F et al.: Oral magnesium pidolate: effects oflong-term administration in patients with sickle cell disease. Br. J. HaematoL (2000) 108(2):284–289.
   PubMed Web of Science ®Google Scholar
• STUART J, MOJIMINIYI FB, STONE PC, CULLIFORD SJ, ELLORY JC: Additive in vitro effects of anti-sickling drugs. Br. J. Haematol. (1994) 86(4):820–823.
   PubMed Web of Science ®Google Scholar
• ORRINGER: EP, CASELLA JF, ATAGA KI et al.: Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: A randomized controlled trial. /AMA (2001) 286(17):2099–2106.
   Google Scholar
• OU J, OU Z, JONES DW et al.: L-4F, an apolipoprotein A-1 mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease. Circulation (2003) 107(18):2337–2341.
   PubMed Web of Science ®Google Scholar
• KEAN LS, MANCI EA, PERRY J: Chimerism and cure: hematologic and pathologic correction of murine sickle cell disease. Blood (2003) 102(13):4582–4593.
   PubMed Web of Science ®Google Scholar
• HAYASHI S, ABDULMALIK 0, PERANTEAU WH et al.: Mixed chimerism following in utero hematopoietic stem cell transplantation in murine models ofhemoglobinopathy. Exp. Hematol. (2003) 31(2):176–184.
   Google Scholar
• IANNONE R, LUZNIK L, ENGSTROM LW et al.: Effects of mixed hematopoietic chimerism in a mouse model of bone marrow transplantation for sickle cell anemia. Blood (2001) 97(12):3960–3965.
   PubMed Web of Science ®Google Scholar
• REED W, WALTERS M., TRACHTENBERG E, SMITH R, LUBIN BH: Sibling donor cord blood banking for children with sickle cell disease. Pediatr. PathoL MoL Med. (2001) 20(2):167–174.
   PubMed Web of Science ®Google Scholar
• LOCATELLI F, ROCHA V, REED W et al.: Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. Blood (2003) 101(6):2137–2143.
   PubMed Web of Science ®Google Scholar
• HE Z, RUSSELL JE: Antisickling effects of an endogenous human a-like globin. Nat. Med. (2004) 10(4):365–367.
   PubMed Web of Science ®Google Scholar
• ADACHI K, SEGAL R, ASAKURA T: Nucleation-controlled aggregation of deoxyhemoglobin S. Participation of hemoglobin F in the aggregation of deoxyhemoglobin S in concentrated phosphate buffer. J. Biol. Chem. (1980) 255(10:7595–7603.
   Google Scholar
• •Demonstrates that HbF does incorporate into HbS polymers.
   Google Scholar
• NAGEL RL, BOOKCHIN RM, JOHNSON J et al.: Structural bases of the inhibitory effects of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S. Proc. Natl. Acad. Sci. USA (1979) 76(2):670–672.
   PubMed Web of Science ®Google Scholar
• ROSENTHAL F, WISLICKI L, KOLLER R: auUber die Bziehungen von schwertsen Blutgiften zu Abauprodukten desEinweisses: em Beitrag zum Enstehungmechanismus der pernizosen Anemie. Klin. Wochenschr. (1928) 7:972.
   Google Scholar
• CHARACHE S, TERRIN ML, MOORE RD et aL: Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N EngL J Med. (1995) 332(20):317–322.
   Google Scholar
• ••Reports the efficacy of hydroxyurea inSCD in a US multi-centre study. The results of this study contributed to the rapid approval of HU by the FDA.
   Google Scholar
• COKIC VP, SMITH RD, BELESLIN -COKIC BB et al.: Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. j Clin. Invest. (2003) 111(2):231–239.
   Google Scholar
• ••Describes the implication of NO in theinduction of HbF by hydroxyurea.
   Google Scholar
• JIANG J, JORDAN SJ, BARR DP, GUNTHER MR, MAEDAH, MASON RP: In vivo production of nitric oxide in rats after administration of hydroxyurea. MoL PharmacoL (1997) 52(6):1081–1086.
   PubMed Web of Science ®Google Scholar
• SAUNTHARARAJAH Y, DESIMONE J: Clinical studies with fetal hemoglobin-enhancing agents in sickle cell disease. Semin. HematoL (2004) 41(4, Supp1.6):11–16.
   Google Scholar
• SAUNTHARARAJAH Y, HILLERY CA, LAVELLE D et al.: Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood (2003) 102(12):3865–3870.
   PubMed Web of Science ®Google Scholar
• ••Describes the efficacy of decitabine in SCDpatients who were nonresponsive to hydroxyurea therapy.
   Google Scholar
• SAUNTHARARAJAH Y, LAVELLE D, DESIMONE J: DNA hypo-methylating agents and sickle cell disease. Br. J. HaematoL (2004) 126(5):629–636.
   PubMed Web of Science ®Google Scholar
• DEBAUN MR: Issues regarding study design for initial clinical trials using decitabine. Semin. HematoL (2004) 41(4, Supp1.6):23–27.
   Google Scholar
• ELFORD HL, WAMPLER GL, VAN'T RIET B: New ribonucleotide reductase inhibitors with antineoplastic activity. Cancer Res. (1979) 39(3):844–851.
   PubMed Web of Science ®Google Scholar
• PACE BS, ELFORD HI, STAMATOYANNOPOULOS G: Transgenic mouse model of pharmacologic induction of fetal hemoglobin: studies using a new ribonudeotide reductase inhibitor, Didox. Am. J. HematoL (1994) 45(2):136–141.
   PubMed Web of Science ®Google Scholar
• SZEKERES T, FRITZER M, STROBL H et al.: Synergistic growth inhibitory and differentiating effects of trimidox and tiazofurin in human promyelocytic leukemia HL-60 cells. Blood (1994) 84(12):4316–4321.
   PubMed Web of Science ®Google Scholar
• IYAMU EW, ADUNYAH SE, ELFORD HL, FASOLD H, TURNER EA: Trimidox-mediated morphological changes during erythroid differentiation is associated with the stimulation of hemoglobin and F-cell production in human K562 cells. Biochem. Biophys. Res. Commun. (1998) 247(3):759–764.
   PubMed Web of Science ®Google Scholar
• IYAMU WE, ADUNYAH SE, FASOLD H et al.: Enhancement of hemoglobin and F-cell production by targeting growth inhibition and differentiation of K562 cells with ribonudeotide reductase inhibitors (didox and trimidox) in combination with streptozotocin. Am. J. HematoL (2000) 63(4):176–183.
   PubMed Web of Science ®Google Scholar
• KOLLANDER R, SOLOVEY A, CHOONG S et al.: Therapeutic inhibition of endothelial tissue factor expression by nitric oxide and other agents in sickle transgenic mice. 28th Annual Meeting of the National Sickle Cell Disease program. Cincinnati OH, USA (2005).
   Google Scholar
• BEDDELL CR, GOODFORD PJ, KNEEN G, WHITE RD, WILKINSON S, WOOTTON R: Substituted benzaldehydes designed to increase the oxygen affinity of human haemoglobin and inhibit the sickling of sickle erythrocytes. Br. J. PharmacoL (1984) 82(2):397–407.
   PubMed Web of Science ®Google Scholar
• BEDDELL CR, KNEEN G, WHITE RD: The anti-sickling activity of a series of aromatic aldehydes [proceedings]. Br. J. PharmacoL (1979) 66(1):70P.
   Web of Science ®Google Scholar
• ZAUGG RH, WALDER JA, KLOTZ IM: Schiff base adducts of hemoglobin. Modifications that inhibit erythrocyte sickling. J. Biol. Chem. (1977) 252(23):8542–8548.
   Google Scholar
• •First published studies on the chemical modification of HbS by aldehydes.
   Google Scholar
• FITZHARRIS P, MCLEAN AE, SPARKS RG, WEATHERLEY BC, WHITE RD, WOOTTON R: The effects in volunteers of BW12C, a compound designed to left-shift the blood-oxygen saturation curve. Br. J. an. Pharmacol. (1985) 19(4):471–481.
   Web of Science ®Google Scholar
• KEIDAN AJ, FRANKLIN IM, WHITE RD, JOY M, HUEHNS ER, STUART J: Effect of BW12C on oxygen affinity of haemoglobin in sickle-cell disease. Lancet (1986) 1(8485):831–834.
   PubMed Web of Science ®Google Scholar
• MERRETT M, STAMMERS DK, WHITE RD: WOOTTON R, KNEEN G: Characterization of the binding of the anti-sickling compound, BW12C, to haemoglobin. Biochem. j (1986) 239(2):387–392.
   PubMed Web of Science ®Google Scholar
• ZHANG C, LI X, LIAN L et ell.: Anti -sickling effect of MX-1520, a prodrug of vanillin: an in vivo study using rodents. Br. J. Haematol (2004) 125(6):788–7895.
   Google Scholar
• STOCKER JW, DE FRANCESCHI L, MCNAUGHTON-SMITH GA, CORROCHER R, BEUZARD BRUGNARA YC: ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice. Blood (2003) 101(6):2412–2418.
   PubMed Web of Science ®Google Scholar
• ••Describes amelioration of RBCdehydration, an important therapeutic pathway in a transgenic mouse model of SCD using a novel Gardos channel blocker.
   Google Scholar
• ATAGA KI, DECASTRO LM, SWERDLOW P, SAUNTHARARAJAH Y, SMITH W: Efficacy and safety of the Gardos channel inhibitor, ICA-17043, in patients with sickle cell anemia. Abstract 103. American Society of Hematology 46th Annual Meeting. San Diego, CA, USA (2004).
   Google Scholar
• •Reports the preliminary results of clinical trials on a novel Gardos channel inhibitor.
   Google Scholar
• DE FRANCESCHI L, BRUGNARA C, BEUZARD Y: Dietary magnesium supplementation ameliorates anemia in a mouse model of beta-thalassemia. Blood (1997) 90(3):1283–90.
   PubMed Web of Science ®Google Scholar
• BRUGNARA C: Sickle cell disease: from membrane pathophysiology to novel therapies for prevention of erythrocyte dehydration. J. Pediatr. Hematol Oncol. (2003) 25(12):927–33.
   PubMed Web of Science ®Google Scholar
• LIAN LR, OLLINGER F, LI X et al: Prevention of hypoxia-induced acute chest syndrome in transgenic sickle mice by flocor. Abstract 1863. American Society of Hematology 41st Annual Meeting. New Orleans, LA, USA (1999).
   Google Scholar
• GLADWIN MT, SCHECHTER AN: Nitric oxide therapy in sickle cell disease. Semin. Hematol. (2001) 38(4):333–342.
   PubMed Web of Science ®Google Scholar
• •Reviews in elegant detail the potential use of NO therapy in SCD.
   Google Scholar
• HEAD CA, BRUGNARA C, MARTINEZ-RUIZ R et al: Low concentrations of nitric oxide increase oxygen affinity of sickle erythrocytes in vitro and in vivo. J. Clin. Invest. (1997) 100(5):1193–1198.
   PubMed Web of Science ®Google Scholar
• MARTINEZ-RUIZ R, MONTERO -HUERTA P, HROMI J, HEAD CA: Inhaled nitric oxide improves survival rates during hypoxia in a sickle cell (SAD) mouse model. Anesthesiology (2001) 94(6):1113–1118.
   PubMed Web of Science ®Google Scholar
• WEINER DL, HIBBERD PL, BETIT P, COOPER AB, BOTELHO CA, BRUGNARA C: Preliminary assessment of inhaled nitric oxide for acute vaso-occlusive crisis in pediatric patients with sickle cell disease. JAMA (2003) 289(9):1136–1142.
   PubMed Web of Science ®Google Scholar
• OKPALA I, DANIEL Y, HAYNES R, ODOEMENE D, GOLDMAN J: Relationship between the clinical manifestations of sickle cell disease and the expression of adhesion molecules on white blood cells. Eur. j Haematol (2002) 69(3):135–144.
   PubMed Web of Science ®Google Scholar
• ANYAEGBU CC, OKPALA IE, AKREN'OVA YA, SALIMONU LS: Peripheral blood neutrophil count and candidacidal activity correlate with the clinical severity of sickle cell anaemia (SCA). Eur. J. Haematol (1998) 60(4):267–268.
   PubMed Web of Science ®Google Scholar
• ••Demonstrates, for the first time, acorrelation between absolute neutrophil counts and SCD severity in patients.
   Google Scholar
• CASTRO 0, BRAMBILLA DJ, THORINGTON B et al.: The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease. Blood (1994) 84(2):643–649.
   Google Scholar
• KINNEY TR, SLEEPER LA, WANG WC et al.: Silent cerebral infarcts in sickle cell anemia: a risk factor analysis. The Cooperative Study of Sickle Cell Disease. Pediatrics (1999) 103(3):640–645.
   PubMed Web of Science ®Google Scholar
• OHENE-FREMPONG K, WEINER SJ, SLEEPER LA et al.: Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood (1998) 91(1):288–294.
   PubMed Web of Science ®Google Scholar
• POWARS DR: Management of cerebral vasculopathy in children with sickle cell anaemia. Br. J. Haematol (2000) 108(4):666–678.
   PubMed Web of Science ®Google Scholar
• BLOUIN MJ, BEAUCHEMIN H, WRIGHT A et al.: Genetic correction of sickle cell disease: insights using transgenic mouse models. Nat. Med. (2000) 6(2):177–182.
   PubMed Web of Science ®Google Scholar
• MCCUNE SL, REILLY MP, CHOMO MJ, ASAKURA T, TOWNES TM: Recombinant human hemoglobins designed for gene therapy of sickle cell disease. Proc. Natl Acad. Sci. USA (1994) 91(21):9852–9856.
   PubMed Web of Science ®Google Scholar
• •Describes procedures for designing recombinant human haemoglobins for SCD therapy.
   Google Scholar
• RUBIN JE, PASCERI P, WU X, LEBOULCH P, ELLIS J: Locus control region activity by 5'H53 requires a functional interaction with 0-globin gene regulatory elements: expression of novel 0/y-globin hybrid transgenes. Blood (2000) 95(10):3242–3249.
   PubMed Web of Science ®Google Scholar
• TAKEKOSHI KJ, OH YH, WESTERMAN KW, LONDON IM, LEBOULCH P: Retroviral transfer of a human 0-globin/.5-globin hybrid gene linked to 13 locus control region hypersensitive site 2 aimed at the gene therapy of sickle cell disease. Proc. Natl Acad. Sci.: USA (1995) 92(7):3014–3018.
   Google Scholar
• PAWLIUK R, WESTERMAN KA, FABRY ME et al.: Correction of sickle cell disease in transgenic mouse models by gene therapy. Science (2001) 294(5550):2368–2371.
   PubMed Web of Science ®Google Scholar
• ••Describes, for the first time, completecorrection of SCD pathophysiology in transgenic mouse models using a lentiviral vector.
   Google Scholar